1. Age 18 or greater

2. Able to obtain informed consent from patient or appropriate designee

3. Possible autoimmune encephalitis as defined by Table 1:

1. Reasonable exclusion of alternative causes

2. Subacute onset (\< 3 months) of memory deficits, altered consciousness, and/or psychiatric symptoms

3. One or more of the following:

* CSF (cerebrospinal fluid) pleocytosis (\>5 cells/µl corrected, if necessary, for traumatic lumbar puncture)

* EEG (electroencephalogram) with epileptiform or focal slow wave abnormalities involving temporal lobes

* Brain abnormalities on T2/FLAIR MRI restricted to the mesial temporal (limbic) lobes

* Associated dyskinesias (faciobrachial dystonic movements or orofacial dyskinesias)

4. Completed initial treatment with iv steroids (at least 3000mg solumedrol) and plasma exchange (at least 3 exchanges) within the past 8 weeks

5. Presence of one (or more) of the following autoantibodies in serum or CSF

* NMDA receptor

* LGI1

* CASPR2

* DPPX

Efficacy of Ocrelizumab in Autoimmune Encephalitis